Logo

Takeda Signs a Licensing Option Agreement with Emendo Biotherapeutics for its OMNI Nuclease Program

Share this

Takeda Signs a Licensing Option Agreement with Emendo Biotherapeutics for its OMNI Nuclease Program

Shots:

  • Emendo to receive convertible notes from Takeda Ventures- will convert it into SeriesB funding utilizing it to advance its gene editing discovery platform & biotherapies into clinical trials. Takeda to get an option to utilize Emendo’s OMNI nuclease program in editing of two genes
  • Emendo will also utilize its gene editing platform to optimize the OMNI nuclease for Takeda's targeted genes
  • OMNI nuclease is a gene editing program which optimizes per target sequence to develop therapies for genetic diseases by specifically editing a gene

Ref: PRNewwire | Image:Takeda

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions